Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine

AIDS. 2001 Apr 13;15(6):799-800. doi: 10.1097/00002030-200104130-00017.

Authors

G J Moyle¹, B G Gazzard

Affiliation

¹ Kobler Clinic, Chelsea and Westminster Hospital, London, UK.

PMID: 11371696
DOI: 10.1097/00002030-200104130-00017

No abstract available

MeSH terms

Anti-HIV Agents / adverse effects*
Anti-HIV Agents / therapeutic use
DNA Mutational Analysis
Didanosine / pharmacology
Didanosine / therapeutic use
Drug Resistance, Microbial
Drug Resistance, Multiple
Drug Therapy, Combination
HIV Infections / drug therapy*
HIV Infections / enzymology
HIV-1 / drug effects
HIV-1 / genetics*
Humans
Lamivudine / pharmacology
Lamivudine / therapeutic use
Mutation
RNA-Directed DNA Polymerase / genetics*
Reverse Transcriptase Inhibitors / pharmacology*
Reverse Transcriptase Inhibitors / therapeutic use
Stavudine / pharmacology
Stavudine / therapeutic use

Substances

Anti-HIV Agents
Reverse Transcriptase Inhibitors
Lamivudine
Stavudine
RNA-Directed DNA Polymerase
Didanosine